Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $415 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $415.
January 12, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterates an Overweight rating on Vertex Pharmaceuticals and maintains a $415 price target.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst could lead to increased investor confidence in Vertex Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100